Bildkälla: Stockfoto

Orexo: Gesynta Pharma reports clinical phase II trial results - Redeye

Redeye comments on Orexo’s announcement of Gesynta Pharma’s results of its clinical phase II trial with OX-MPI (GS-248).

Redeye comments on Orexo’s announcement of Gesynta Pharma’s results of its clinical phase II trial with OX-MPI (GS-248).
Börsvärldens nyhetsbrev
ANNONSER